Temozolomide Clinical Trials
84 recruitingDrug
Phase 248Phase 141Phase 312Early Phase 14Not Applicable1
Showing 1–20 of 84 trials
Recruiting
Phase 3
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
NeuroblastomaGanglioneuroblastoma, Nodular
National Cancer Institute (NCI)478 enrolled178 locationsNCT06172296
Recruiting
Phase 1Phase 2
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Glioblastoma IDH (Isocitrate Dehydrogenase) WildtypeAstrocytoma, Grade III
Debiopharm International SA116 enrolled16 locationsNCT05765812
Recruiting
Phase 1Phase 2
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
Hematopoietic and Lymphatic System NeoplasmMetastatic Malignant Solid NeoplasmStage IV Colorectal Cancer AJCC v8+4 more
National Cancer Institute (NCI)42 enrolled23 locationsNCT05691491
Recruiting
Phase 2Phase 3
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Glioblastoma
Global Coalition for Adaptive Research2,250 enrolled63 locationsNCT03970447
Recruiting
Phase 1
Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
GlioblastomaGliosarcoma
Memorial Sloan Kettering Cancer Center60 enrolled11 locationsNCT06934889
Recruiting
Phase 1Phase 2
Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain
Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic MelanomaPathologic Stage IV Cutaneous Melanoma AJCC v8+1 more
Kari Kendra24 enrolled1 locationNCT05588453
Recruiting
Phase 2
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company65 enrolled40 locationsNCT07015242
Recruiting
Phase 2
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium62 enrolled13 locationsNCT06450041
Recruiting
Early Phase 1
Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation
NeuroblastomaPineoblastomaAtypical Teratoid/Rhabdoid Tumor+11 more
C17 Council15 enrolled12 locationsNCT06942039
Recruiting
Phase 3
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
GlioblastomaGBMRecurrent Glioblastoma
CarThera560 enrolled48 locationsNCT05902169
Recruiting
Phase 2
A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma
Neuroblastoma Recurrent
St. Jude Children's Research Hospital54 enrolled4 locationsNCT07085338
Recruiting
Phase 3
IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
Relapsed/Refractory Primary Central Nervous System Lymphoma
Ono Pharmaceutical Co., Ltd.132 enrolled14 locationsNCT07104032
Recruiting
Phase 1
A Study of 177Lu-PSMA-617 in People With Gliomas
GliomaGlioblastoma, IDH-wildtypeDiffuse Midline Glioma, H3 K27-Altered+3 more
Memorial Sloan Kettering Cancer Center20 enrolled7 locationsNCT07223034
Recruiting
Phase 2
Pan Tumor Rollover Study
Cancer
Bristol-Myers Squibb1,500 enrolled399 locationsNCT03899155
Recruiting
Phase 1Phase 2
VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
Solid TumorRhabdomyosarcoma
University of Texas Southwestern Medical Center23 enrolled7 locationsNCT04796012
Recruiting
Phase 3
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
Glioblastoma
GT Medical Technologies, Inc.766 enrolled5 locationsNCT07195591
Recruiting
Phase 1Phase 2
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
CancerBrain TumorBrain Cancer+6 more
Northwell Health67 enrolled1 locationNCT03213002
Recruiting
Phase 2
Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas
Malignant Solid NeoplasmLung Neuroendocrine NeoplasmDigestive System Neuroendocrine Neoplasm+1 more
Roswell Park Cancer Institute60 enrolled1 locationNCT06202066
Recruiting
Early Phase 1
Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma
Glioblastoma
Washington University School of Medicine12 enrolled1 locationNCT06831526
Recruiting
Phase 1
Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
Neuroblastoma
National Cancer Institute (NCI)40 enrolled1 locationNCT06995872